Clinical and Laboratory Studies of Malignant Lymphomas

恶性淋巴瘤的临床和实验室研究

• 批准号: 7261224
• 负责人: RONALD LEVY
• 金额: $ 166.22万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-06-27 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7261224
• 关键词: Clinical; Laboratory; Studies; Malignant; Lymphomas

DESCRIPTION (provided by applicant): The overall theme of our program is to understand the signals that cause and that regulate malignant lymphomas. Our focus is on the immune system, since these tumors are derived from the cells of the immune system. We plan to extend findings made in our current program and to take advantage of new technology that we have helped develop. To enable our work we have access to large numbers of patients with lymphoma, and we have built a tumor tissue bank and clinical database extending over several decades. Specific Projects: 1.We are developing a new strategy for inducing an immune response against lymphoma. Immune signaling molecules are injected directly into the tumor at one site in conjunction with the induction of apoptosis/necrosis at that same site. We will conduct a prototype clinical trial and test preclinical animal models 2. Our goal is to discover the signal transduction pathways that govern clinical behavior of lymphomas. A new method of flow cytometry for intracellular signaling pathways will be used on lymphoma specimens. Differences between tumors will be related to clinical outcome. The signaling relationships between tumor and host immune cells will be interrogated and new targets will be sought. 3. A transgenic mouse develops lymphoma as a result of an activated MYC gene. These lymphomas regress when the MYC gene is turned off, but only when the host has an intact immune system. We will determine whether this control is due to an immune response or to signals that regulate lymphoid homeostasis.

描述（由申请人提供）：我们项目的总体主题是了解导致和调节恶性淋巴瘤的信号。我们的重点是免疫系统，因为这些肿瘤源自免疫系统的细胞。我们计划扩展我们当前计划中的发现，并利用我们帮助开发的新技术。为了开展我们的工作，我们接触了大量的淋巴瘤患者，并建立了长达数十年的肿瘤组织库和临床数据库。 具体项目： 1.我们正在开发一种诱导针对淋巴瘤的免疫反应的新策略。将免疫信号分子直接注射到肿瘤的一个部位，同时诱导该部位的细胞凋亡/坏死。我们将进行原型临床试验并测试临床前动物模型 2. 我们的目标是发现控制淋巴瘤临床行为的信号转导途径。一种用于细胞内信号通路的流式细胞术的新方法将用于淋巴瘤标本。肿瘤之间的差异与临床结果有关。肿瘤和宿主免疫细胞之间的信号传导关系将受到质疑，并寻找新的靶点。 3. 转基因小鼠因 MYC 基因激活而患上淋巴瘤。当 MYC 基因关闭时，这些淋巴瘤就会消退，但前提是宿主具有完整的免疫系统。我们将确定这种控制是由于免疫反应还是由于调节淋巴稳态的信号。